Association of fulminant non-A non-B hepatitis with homozygosity for HLA A1-B8-DR3

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 4, 2005, Pages 555-561

  Gow, Paul ^a   Hathaway, Mark ^b   Gunson, Bridget ^b   Heward, Joanne ^c   Mutimer, David ^b,c  

^a AUSTIN HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Autoimmune hepatitis; HLA; Homozygosity; Non A non B hepatitis; Tumor necrosis factor

Indexed keywords

AUTOANTIBODY; HLA A1 ANTIGEN; HLA B8 ANTIGEN; HLA DR3 ANTIGEN; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE HEPATITIS; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; HAPLOTYPE; HEPATITIS NON A NON B; HETEROZYGOSITY; HLA TYPING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER FAILURE; MAJOR CLINICAL STUDY; NORTH AMERICA; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; WESTERN EUROPE;

EID: 19944382474     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03605.x     Document Type: Article

References (37)

1. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J. Hepatol 1997; 26: 62-8.
2. Schiodt FV, Atillasoy E, Shakil AO et al. Aetiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl. Surg. 1999; 5: 29-34.
3. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002; 137: 947-54.
4. Hoofnagle JH, Carithers RL Jr, Shapiro C et al. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21: 240-52.
5. Yanagi M, Kaneko S, Unoura M, Murakami S et al. Hepatitis C virus in fulminant hepatic failure. N. Engl. J. Med. 1991; 324: 1895-6.
6. Heringlake S, Osterkamp S, Trautwein C et al. Association between fulminant hepatic failure and a strain of GBV virus C. Lancet 1996; 3048: 1626-9.
7. Charlton M, Adjei P, Poterucha J et al. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology 1998; 28: 839-42.
8. Mutimer D, Shaw J, Neuberger J et al. Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A non-B hepatitis. Gut 1995; 36: 433-6.
9. Moaven LD, Locarnini SA, Bowden DS et al. Hepatitis G virus and fulminant hepatic failure: evidence for transfusion-related infection. J. Hepatol. 1997; 27: 613-19.
10. Saiz JC, Sans M, Mas A et al. Hepatitis G virus infection in fulminant hepatic failure. Gut 1997; 41: 696-9.
11. Gimenez-Barcons M, Forns X, Ampurdanes S et al. Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J. Hepatol. 1999; 30: 1028-34.
12. Ferraz ML, Silva AE, Macdonald GA et al. Fulminant hepatitis in patients undergoing liver transplantation: evidence for a non-A, non-B, non-C, non-D, and non-A syndrome. Liver Transpl. Surg. 1996; 2: 60-6.
13. Sallie R, Silva AE, Purdy M et al. Hepatitis C and E in non-A non-B fulminant hepatic failure: a polymerase chain reaction and serological study. J. Hepatol. 1994; 20: 580-8.
14. Rochling FA, Jones WF, Chau K et al. Acute sporadic non-A, non-B, non-C, non-D, non-D, non-A hepatitis. Hepatology 1997; 25: 478-83.
15. Gimson AE, O'Grady J, Ede RJ et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288-94.
16. Ellis AJ, Saleh M, Smith H et al. Late-onset hepatic failure: clinical features, serology and outcome following transplantation. J. Hepatol. 1995; 23: 363-72.
17. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog. Liver Dis. 1970; 3: 282-98.
18. Terasaki P, McClelland JD, Park MS et al. In: Ray JG, Hare DB, Pederson PD, Kayhoe DE, eds. Manual of Tissue Typing Techniques. Washington, DC: Department of Health, Education and Welfare Publications, 1974; 75-545.
19. Bunce M, O'Neill CM, Barnardo MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, and DQB1 by PCR with 144 primer mixes utilising sequence-specific primers. Tissue Alleles 1995; 46: 35-67.
20. Schreuder GM, Hurley CK, Marsh SG et al. The HLA dictionary 2001: a summary of HLA-A-B-C-DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A-B-C-DR and -DQ antigens. Eur. J. Immunogenet. 2001; 28: 565-96.
21. Degli-Esposti MA, Leaver AL, Christiansen FT et al. Ancestral haplotypes: conserved population MHC haplotypes. Hum. Immunol. 1992; 34: 242-52.
22. Ulgiati D, Townend DC, Christiansen FT et al. Complete sequence of the complement C4 gene from the HLA-A1, B8, C4AQ0, C4B1, DR3 haplotype. Immunogenetics 1996; 43: 250-2.
23. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997; 34: 391-9.
24. Kelly H, McCann VJ, Kay PH et al. Susceptibility to IDDM is marked by MHC supratypes rather than individual alleles. Immunogenetics 1985; 22: 643-51.
25. Hartung K, Baur MP, Coldewey R et al. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J. Clin. Invest. 1992; 90: 1346-51.
26. Sachs JA, Awad J, McCloskey D et al. Different HLA associated gene combinations contribute to susceptibility for coeliac disease and dermatitis herpetiformis. Gut 1986; 27: 515-20.
27. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38-41.
28. Donaldson PT, Doherty DG, Hayllar KM et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte alleles DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6.
29. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M et al. HLA-associated non-responsiveness to hepatitis B vaccine. Tissue Alleles 1990; 35: 60-3.
30. Vento S. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J. Viral Hepat. 2000; 7 (Suppl. 1): 7-8.
31. Cameron PU, Mallal SA, French MA et al. Major histocompatibility complex genes influence the outcome of HIV infection. Ancestral haplotypes with C4 null alleles explain diverse HLA associations. Hum. Immunol. 1990; 29: 282-95.
32. Czaja AJ, Strettell MD, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
33. Manns MP, Bremm A, Schneider PM et al. HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 1991; 101: 1367-73.
34. Kuwada SK, Patel VM, Hollinger FB et al. Non-A, non-B fulminant hepatitis is also non-E and non-C. Am. J. Gastroenterol. 1994; 89: 57-61.
35. Wright TL, Mamish D, Combs C et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992; 339: 952-5.
36. Pagan EA, Harrison TJ. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J. Hepatol. 1994; 21: 587-91.
37. Laskus T, Rakela J, Wiesner RH et al. Lack of evidence for hepatitis B virus (HBV) infection in fulminant non-A, non-B hepatitis. Dig. Dis. Sci. 1994; 39: 1677-82.